# Invivyd, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Invivyd, Inc.). ## Overview Invivyd, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. Its first authorized product, PEMGARDA (pemivibart), is designed to provide ongoing protection against SARS-CoV-2 despite viral evolution, and the company is also advancing additional product candidates such as VYD2311. ## Products & services • PEMGARDA (pemivibart) authorized mAb for COVID-19 prevention • VYD2311 next-generation monoclonal antibody candidate • Discovery and preclinical antibody engineering • Clinical development of antiviral mAb programs • Commercial distribution of authorized biologic product - **Authorized product sales** (85%) — Sales of PEMGARDA in the U.S. through specialty distributors and direct accounts. - **Pipeline development** (10%) — Discovery, preclinical, and clinical development of next-generation mAb candidates such as VYD2311. - **Commercial support and distribution** (5%) — Third-party logistics, customer service, and distribution infrastructure supporting product delivery. - PEMGARDA (pemivibart) authorized monoclonal antibody for COVID-19 prevention - VYD2311 next-generation monoclonal antibody product candidate - Discovery and preclinical development of antiviral mAbs - Clinical development and regulatory advancement of product candidates - Commercial distribution and logistics for biologic products ## Customers Invivyd sells primarily into the U.S. healthcare channel, with PEMGARDA purchased by third-party specialty distributors and a smaller number of infusion centers, healthcare providers, and provider institutions. The end users are patients at risk of serious viral infectious disease, while the buying decision is driven by hospitals, clinics, and distributors that manage access, reimbursement, and site-of-care logistics. - **Specialty distributors** (primary) — Buy PEMGARDA for resale and distribution to sites of care; important because they handle channel access and logistics. - **Infusion centers** (primary) — Purchase directly or through distributors to administer PEMGARDA in outpatient settings. - **Healthcare providers and provider institutions** (primary) — Hospitals, clinics, and provider groups that buy and administer the product for eligible patients. - **Payers and reimbursement stakeholders** (secondary) — Not direct product customers, but they determine net realization through coverage and billing rules. - Specialty distributors buying PEMGARDA for downstream healthcare delivery - Infusion centers purchasing directly for administration to patients - Healthcare providers and provider institutions using the product in care settings - Payers and billing systems that influence adoption through reimbursement - Patients at risk of serious viral infectious disease as the end beneficiaries ## Geography Invivyd’s commercial revenue is currently concentrated in the United States, where PEMGARDA is sold under a traditional commercial distribution model. The company also maintains trademark filings and registrations in several international markets, but its operating and revenue footprint remains overwhelmingly U.S.-centric. - **United States** (100%) — PEMGARDA product revenue is disclosed as U.S.-only in the report excerpts. - U.S. is the only disclosed revenue market for PEMGARDA - Sales flow through specialty distributors and direct healthcare accounts - Commercial sites include infusion centers, clinics, and provider institutions - International activity is mainly IP/trademark coverage, not disclosed revenue - Geographic concentration increases dependence on U.S. regulatory and reimbursement access ## Strategy Invivyd’s strategy is to build a commercial franchise around PEMGARDA while advancing next-generation monoclonal antibodies that can keep pace with viral evolution. The company is also expanding its sales, marketing, market access, and distribution capabilities so it can support commercialization without relying entirely on external partners. - **Expand PEMGARDA commercialization** (short-term) — Current revenue depends on adoption of the first authorized product and access to sites of care. - **Build internal commercial capabilities** (short-term) — The company needs sales, marketing, and market access capacity to support product uptake and future launches. - **Advance next-generation pipeline assets** (medium-term) — Pipeline diversification reduces dependence on a single authorized product and addresses viral evolution risk. - **Secure manufacturing and supply resilience** (medium-term) — Commercial continuity depends on third-party CDMO access and uninterrupted supply of biologic product. - Grow PEMGARDA adoption in the U.S. commercial channel - Expand sales, marketing, and market access infrastructure - Advance VYD2311 and future mAb candidates - Use third-party manufacturing and logistics to scale supply - Build brand awareness among clinicians and care sites ## Risks Invivyd faces the classic risks of an early commercial-stage biotech: dependence on a single authorized product, uncertain market uptake, and heavy reliance on external manufacturing and distribution partners. The company also disclosed substantial doubt about its ability to continue as a going concern, making financing access and Nasdaq compliance especially important near-term risks. - **Going concern and liquidity shortfall** [critical] — Management disclosed that existing cash may not fund operations beyond one year without additional revenue or financing. - **Single-product concentration** [high] — Current product revenue is tied primarily to PEMGARDA, so demand or reimbursement weakness would directly hit sales. - **Manufacturing and supply chain dependence** [high] — The company relies on third-party manufacturers and CDMOs, including foreign contract manufacturers that may face trade or regulatory restrictions. - **Regulatory and scientific obsolescence** [high] — Antibody effectiveness can be undermined by viral evolution, which can reduce clinical and commercial relevance. - **Nasdaq listing compliance** [medium] — The company previously received a minimum bid price deficiency notice and could face future listing pressure if market conditions weaken. - Going-concern risk if cash burn outpaces revenue and financing - Heavy dependence on PEMGARDA for current product revenue - Regulatory and clinical risk if viral evolution reduces product utility - Third-party manufacturing and CDMO concentration risk - Nasdaq listing compliance risk from low share price and equity levels ## Accounting The most important accounting issue is revenue recognition for PEMGARDA, which is recorded net of discounts, distributor fees, chargebacks, returns, and other variable consideration. Because the product is sold through specialty distributors and healthcare sites, estimates around channel inventory, rebates, and returns can materially affect reported revenue and quarterly comparability. - **Revenue recognition and variable consideration** — Can materially change reported product revenue and gross-to-net deductions - **Channel inventory and reserves** — Affects revenue timing and period-to-period comparability - **Going-concern assessment** — Signals financing risk and uncertainty in future operating plans - **R&D and third-party manufacturing costs** — Can create lumpy operating expense patterns and estimate sensitivity - Net revenue is reduced by discounts, fees, chargebacks, and returns - Distributor inventory estimates can change reported revenue timing - Commercial launch creates quarter-to-quarter revenue volatility - R&D and manufacturing costs are heavily judgmental and project-based - Going-concern disclosure signals liquidity assumptions are critical --- *Last updated: 2026-04-28T20:18:19.207918+00:00*